These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Effect of long-term prazosin treatment on certain humoral and metabolic factors in patients with primary hypertension]. Knypl K; Brym E; Czerniewska E; Wocial B; Kuczyńska K; Chodakowska J Pol Tyg Lek; 1991 Jan 7-14; 46(1-3):32-4. PubMed ID: 1845664 [TBL] [Abstract][Full Text] [Related]
5. The effect of small doses of guanfacine (Estulic Sandoz) on the lipid levels and catecholamine excretion in patients with essential hypertension. Balazovjech I; Skultétyová D; Mikulecký M; Kratochvíl'ová H Cor Vasa; 1987; 29(4 Suppl 1):46-52. PubMed ID: 3315451 [TBL] [Abstract][Full Text] [Related]
8. Guanfacine: a new centrally-acting antihypertensive agent. Beevers DG; Bloxham CA; Walker JM Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931 [TBL] [Abstract][Full Text] [Related]
9. [Clinical pharmacology of the antihypertensive action of guanfacine]. Safar M; Weiss Y; Georges D Arch Mal Coeur Vaiss; 1980 Oct; 73(10):1171-7. PubMed ID: 6778409 [TBL] [Abstract][Full Text] [Related]
10. [Effect of 5-month guanfacine treatment on the renin-angiotensin-aldosterone system and some metabolic factors in patients with diabetes mellitus type II and hypertension]. Jaromczyk-Slisz J; Kubasik A; Jasiel-Wojculewicz H; Badzio T; Krupa-Wojciechowska B Pol Tyg Lek; 1992 Nov 16-30; 47(46-48):1045-7. PubMed ID: 1305723 [TBL] [Abstract][Full Text] [Related]
11. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension. Collart F; Staroukine M; Verniory A Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792 [TBL] [Abstract][Full Text] [Related]
13. [Controlled doubleblind study on dose-effect relationship of guanfacine a long-acting hypotensive guanidine derivative (author's transl)]. Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G Arzneimittelforschung; 1980; 30(6):1005-7. PubMed ID: 6998487 [TBL] [Abstract][Full Text] [Related]
14. Guanfacine in the treatment of hypertensives with a pronounced response to exercise and diabetes mellitus. Dvorák I; Podrouzková B; Kocourková J; Kubesová H; Spác J; Nĕmcová H; Blaha M Cor Vasa; 1987; 29(4 Suppl 1):30-6. PubMed ID: 3315448 [TBL] [Abstract][Full Text] [Related]
15. Long term comparative study of guanfacine and alpha-methyldopa in essential hypertension. Rengo F; Ricciardelli B; Volpe M; Trimarco B; Saccà L; Condorelli M Arch Int Pharmacodyn Ther; 1980 Apr; 244(2):281-91. PubMed ID: 6996627 [TBL] [Abstract][Full Text] [Related]
17. Improved exercise performance of hypertensive patients treated with guanfacine (Estulic Sandoz). Bazika V Cor Vasa; 1987; 29(4 Suppl 1):42-5. PubMed ID: 3315450 [TBL] [Abstract][Full Text] [Related]
18. Long-term antihypertensive therapy with guanfacine. Szám I; Holló J Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):388-92. PubMed ID: 6749702 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of arterial hypertension with a single daily dose of guanfacine]. Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438 [No Abstract] [Full Text] [Related]
20. Long-term efficacy and tolerance of the antihypertensive agent guanfacine. Jerie P; Lasance A Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):170-4. PubMed ID: 6370876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]